Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of California, San Francisco |
---|---|
Information provided by: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00508963 |
Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).
Condition | Intervention |
---|---|
Leishmaniasis, Cutaneous Leishmaniasis, Mucocutaneous |
Drug: sodium stibogluconate (Pentostam) |
Study Type: | Expanded Access |
Official Title: | Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jane E Koehler, MA, MD | 415-476-3536 | jkoehler@medicine.ucsf.edu |
United States, California | |
University of CA at San Francisco Hospitals and Clinics | |
San Francisco, California, United States, 94143 |
Principal Investigator: | Timothy Berger, MD | University of CA at San Francisco |
Principal Investigator: | Lindy Fox, MD | University of CA at San Francisco |
Study ID Numbers: | UCSF Infectious Diseases |
Study First Received: | July 27, 2007 |
Last Updated: | April 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00508963 |
Health Authority: | United States: Food and Drug Administration |
New World Cutaneous or Mucocutaneous Leishmaniasis |
Leishmaniasis, Mucocutaneous Leishmaniasis Protozoan Infections Skin Diseases, Infectious |
Antimony Sodium Gluconate Skin Diseases Parasitic Diseases Leishmaniasis, Cutaneous |
Anti-Infective Agents Antiprotozoal Agents Antiparasitic Agents Skin Diseases, Parasitic Antiplatyhelmintic Agents Therapeutic Uses |
Anthelmintics Sarcomastigophora Infections Mastigophora Infections Schistosomicides Pharmacologic Actions |